The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information
Advertisements

The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.
Remote follow up: Where are we now? Has it improved services to our patients? LYDIA BRADLEY CRM DEVICES LEAD PHYSIOLOGIST.
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
What IMPACT Means to Physicians November 2014 Physician Champion: William Bradshaw, MD, FACS.
MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
analysis from the SHIFT study
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
An Emergency Department Diagnostic Protocol For Patients With Transient Ischemic Attack: A Randomized Controlled Trial Michael A. Ross MD Scott Compton.
Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D
Terry Field, D.Sc. Meyers Primary Care Institute University of Massachusetts Medical School, Fallon Community Health Plan, Fallon Clinic.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Benefits of Urgent Evaluation and Treatment for TIA and Minor Stroke Summary and Comment by Kristi L. Koenig, MD, FACEP Published in Journal Watch Emergency.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
MISS Journal Club 2012 Metabolic Surgery & Emerging Technologies Goal: To review 5 important and clinically relevant papers from 2011, on Metabolic Surgery.
Sophie Lanzkron, MD, MHS Associate Professor of Medicine and Oncology Johns Hopkins School of Medicine.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Integrating Monitoring into the Infrastructure and Workflow of Routine Practice Philip B. Adamson, MD Associate Professor of Physiology Director, The Heart.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
INTRODUCTION: INTRODUCTION: implantable cardioverter-defibrillators (ICDs) have clearly demonstrated to terminate an elevated percentage of sustained ventricular.
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Eric J Robinson, M.D. Cardiologist April 25, 2015
R 63 year old widowed, bible carrying, male truck driver A1c = 9.9% (goal
Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,
CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.
Alireza Heidari Bakavoli, MD. Cardiology department Qaem medical center Mashhad University of Medical Science Role of ICD and CRT devices in Heart failure.
SCRIPPS CLINIC A Cost Analysis of Bleed Complications from Two Stroke Prevention Strategies in Non-valvular Atrial Fibrillation: Left Atrial Appendage.
Conference 2009 Nurse 2.0 Engaging the Healthcare Consumer Remote Patient Monitoring Debbie Schmidt RN, MCSE.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.
CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.
1 Status and Recent Activities Face-to-Face meeting at the ISO/TC215 Health Informatics International Working Group Meeting San Francisco, April 20-23,
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Remote Monitoring of Implantable Cardioverter-Defibrillators:
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Reactive ATP and MINERVA
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
EMPHASIS-HF Extended Follow-up
Cardiovacular Research Technologies
How and why this study may change my practice ?
Figure 1 Study flow diagram and definition of clinical response
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Physical Counterpressure Maneuver (PC) Trial
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Presentation transcript:

The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD President, Mid-State Cardiology, a unit of St. Thomas Heart Clinical Professor of Medicine University of Tennessee College of Medicine

Disclosures Medtronic Sponsored study Medtronic: Speaker, research & consulting significant Boston Scientific: speaker St. Jude: research

Study Purpose To demonstrate that remote monitoring with automatic clinician notifications reduces the time from a clinical event to a clinical decision in response to arrhythmias, cardiovascular disease progression, and device issues as compared to standard in-office care. Rates of cardiovascular health care utilization (HCU) between treatment groups

Study Design Randomized, multi-center prospective study –N = 1,997 newly implanted CRT-D and DR-ICD patients –136 US centers –Remote management system vs. standard In-office care –Patients followed remotely for 12 months (Remote Arm) Remote Arm 1014 pts Enrollment In-office Arm 983 pts 1 Month Office F/U Patient signs Informed Consent/HIPAA Authorization implanted with a study device and randomized Enrollment 1 Month Office F/U 3 Month Remote F/U3 Month Office F/U 6 Month Remote F/U6 Month Office F/U 9 Month Remote F/U9 Month Office F/U 12 Month Remote F/U12 Month Office F/U 15 Month Office F/U Crossley G, Boyle A, Vitense H, Sherfesee L, Mead RH. Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study. Am Heart J Nov;156(5): Epub 2008 Sep 11.

Required Study Programming RemoteIn-office Medtronic CareLink® Home MonitorProvidedNot Provided Clinical Management Alerts AT/AF BurdenAutomatic Clinician Alert, 12 hrs/dayOff Fast V. Rate during AT/AFAutomatic Clinician Alert, 120 bpm x ≥ 6 hrs AT/AF /dayOff Number of Shocks DeliveredAutomatic Clinician Alert, 2 Shocks DeliveredOff All Therapies Exhausted in a ZoneAutomatic Clinician AlertOff Lead / Device Integrity Alerts Lead Impedance Out of RangeAutomatic Clinician and Audible Patient AlertAudible Patient Alert VF Detection / Therapy OffAutomatic Clinician and Audible Patient AlertAudible Patient Alert Low Battery VoltageAutomatic Clinician and Audible Patient AlertAudible Patient Alert Excessive Charge TimeAutomatic Clinician and Audible Patient AlertAudible Patient Alert

All events that did or would have triggered alerts if device programmed accordingly included –Events that triggered alerts: the center logged date of clinical decision –Events that did not trigger alerts: date of decision was date of first device interrogation following event –Time to decision determined for each event, and for each subject with an event, these times were averaged –Due to skewness of data, nonparametric test used to compare time to decision per patient between arms For health care utilization, multiple events proportional hazards models used to compare rates of each of the following between arms: –CV hospitalizations –ED visits –Unscheduled clinic visits Study Methods

Study Demographics Patient CharacteristicsRemote (n=1014)In-office (n=983) Male70.5%71.7% Age (years)65.2 ± ± 11.9 CRT-D36.4%35.3% LVEF (%)28.6 ± ± 10.3 NYHA No HF Class I Class II Class III Class IV 5.3% 3.9% 40.9% 48.5% 1.5% 6.7% 4.7% 39.5% 47.5% 1.5%

Primary Endpoint Event to Clinical Decision (median time) (per patient with at least one event) Time from event to clinical decision in the Remote Arm was significantly shorter than in the In-office Arm (p<0.001) Median time in the Remote arm was 4.6 days vs. 22 days in the In-office arm Note: Data includes events for patients who crossed over, were non-compliant or had alerts occur prior to home monitor setup

Time from Event to Decision by Alert Type (median days) Device EventNo. of Events (No. of Patients) No. of Days from Event Onset To Clinical Decision Median (Interquartile Range) RemoteIn-officeRemoteIn-office AT/AF burden at least 12 hrs 437 (107)280 (105)3 (1, 15)24 (7, 57) Fast V rate at least 120 bpm during at least 6 hrs AT/AF 41 (26)47 (37)4 (2, 13)23 (5, 40) At least 2 shocks delivered in an episode 44 (35)32 (23)0 (0, 1.5)0 (0, 2) Lead impedances out of range 26 (18)12 (6)0 (0, 9)17 (5.5, 45) All therapies in a zone exhausted for an episode 16 (12)11 (6)0 (0, 1)9 (0, 36) VF detection/therapy off 10 (10)8 (8)0 (0, 0)0 (0, 84) Low battery 1 (1) 300 Total 575 (172)391 (145)3 (0, 13)20 (4, 52)

Results of Clinician Alert Transmissions (Remote Arm)

Clinician Alert Transmissions

Clinic Visits (Scheduled and Unscheduled) By replacing routine clinic visits with remote monitoring, the observed rate of total clinic visits per patient year was Remote (3.92) vs. In-office (6.27)

Health Care Utilization Visits by Treatment Arm * Includes Urgent Care Visits

Impact of Remote Management Remote Arm = 3.3 days per hospitalization In-office Arm = 4 days per hospitalization Mean reduction 18% Estimated savings per hospitalization $1,659* This study showed the Remote Arm had significantly shorter hospitalization length of stays than In-office Arm (p=0.002) (p = 0.002) * Estimated using the Medicare Limited Data Set - Standard Analytic Files from

Conclusions A significant reduction in time from onset of events to clinical decisions in response to arrhythmias, and device issues Replacement of routine in-clinic follow-up visits with remote transmissions did not increase other health care utilizations (cardiovascular hospitalizations, emergency department, and unscheduled clinic visits) A significant reduction in mean length of stay per cardiovascular hospitalization In this study monitoring patients remotely with automatic clinician alerts showed: